Cargando…

Surgical treatment on infective endocarditis: impact of diabetes on mortality

BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocardit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogan, Alexander, Wieder-Finesod, Anat, Frogel, Jonathan, Peled-Potashnik, Yael, Ram, Eilon, Raanani, Ehud, Sternik, Leonid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248198/
https://www.ncbi.nlm.nih.gov/pubmed/35773698
http://dx.doi.org/10.1186/s12933-022-01557-x
_version_ 1784739320193613824
author Kogan, Alexander
Wieder-Finesod, Anat
Frogel, Jonathan
Peled-Potashnik, Yael
Ram, Eilon
Raanani, Ehud
Sternik, Leonid
author_facet Kogan, Alexander
Wieder-Finesod, Anat
Frogel, Jonathan
Peled-Potashnik, Yael
Ram, Eilon
Raanani, Ehud
Sternik, Leonid
author_sort Kogan, Alexander
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocarditis. METHODS: We performed an observational cohort study in the large tertiary center in Israel during 14 years. All data of patients who underwent surgical treatment of endocarditis, performed between 2006 and 2020 were extracted from the departmental database. Patients were divided into two groups: Group I (non-diabetic patients), and Group II (diabetic patients). RESULTS: The study population includes 420 patients. Group I (non-diabetic patients), comprise 326 patients, and Group II (diabetic patients), comprise 94 patients. Mean follow-up duration was 39.3 ± 28.1 months. Short-term, 30-day and in-hospital mortality, also intermediate-term mortality (1- and 3-year) was higher in the DM group compared with the non-DM group, but did not reach statistical significance: 11.7% vs. 7.7%. (p = 0.215); 12.8% vs. 8.3% (p = 0.285); 20.2% vs. 13.2% (p = 0.1) and 23.4% vs. 15.6% (p = 0.09) respectively. Long-term, 5-year mortality was significantly higher in the DM group, compared to the non-DM group: 30.9% vs. 16.6% (p = 0.003). Furthermore, predictors for long-term mortality included diabetes (CI 1.056–2.785, p = 0.029), as demonstrated by regression analysis. CONCLUSIONS: Diabetic patients have trend to increasing mortality at the short- and intermediate period post-surgery for IE, but this is not statistically significant. Survival of diabetic patients deteriorates after more than three years follow surgery. Diabetes is an independent predictor for long-term, 5-year mortality after surgical treatment of endocarditis, regardless of the patients age and comorbidities. Trial registration Ethical Committee of Sheba Medical Centre, Israel on 02.12. 2014, Protocol 4257
format Online
Article
Text
id pubmed-9248198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92481982022-07-02 Surgical treatment on infective endocarditis: impact of diabetes on mortality Kogan, Alexander Wieder-Finesod, Anat Frogel, Jonathan Peled-Potashnik, Yael Ram, Eilon Raanani, Ehud Sternik, Leonid Cardiovasc Diabetol Research BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients suffering from infective endocarditis (IE). The aim of the study was to evaluate the impact of type 2 DM on the early-, intermediate- and long-term mortality of patients who underwent surgical treatment of endocarditis. METHODS: We performed an observational cohort study in the large tertiary center in Israel during 14 years. All data of patients who underwent surgical treatment of endocarditis, performed between 2006 and 2020 were extracted from the departmental database. Patients were divided into two groups: Group I (non-diabetic patients), and Group II (diabetic patients). RESULTS: The study population includes 420 patients. Group I (non-diabetic patients), comprise 326 patients, and Group II (diabetic patients), comprise 94 patients. Mean follow-up duration was 39.3 ± 28.1 months. Short-term, 30-day and in-hospital mortality, also intermediate-term mortality (1- and 3-year) was higher in the DM group compared with the non-DM group, but did not reach statistical significance: 11.7% vs. 7.7%. (p = 0.215); 12.8% vs. 8.3% (p = 0.285); 20.2% vs. 13.2% (p = 0.1) and 23.4% vs. 15.6% (p = 0.09) respectively. Long-term, 5-year mortality was significantly higher in the DM group, compared to the non-DM group: 30.9% vs. 16.6% (p = 0.003). Furthermore, predictors for long-term mortality included diabetes (CI 1.056–2.785, p = 0.029), as demonstrated by regression analysis. CONCLUSIONS: Diabetic patients have trend to increasing mortality at the short- and intermediate period post-surgery for IE, but this is not statistically significant. Survival of diabetic patients deteriorates after more than three years follow surgery. Diabetes is an independent predictor for long-term, 5-year mortality after surgical treatment of endocarditis, regardless of the patients age and comorbidities. Trial registration Ethical Committee of Sheba Medical Centre, Israel on 02.12. 2014, Protocol 4257 BioMed Central 2022-06-30 /pmc/articles/PMC9248198/ /pubmed/35773698 http://dx.doi.org/10.1186/s12933-022-01557-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kogan, Alexander
Wieder-Finesod, Anat
Frogel, Jonathan
Peled-Potashnik, Yael
Ram, Eilon
Raanani, Ehud
Sternik, Leonid
Surgical treatment on infective endocarditis: impact of diabetes on mortality
title Surgical treatment on infective endocarditis: impact of diabetes on mortality
title_full Surgical treatment on infective endocarditis: impact of diabetes on mortality
title_fullStr Surgical treatment on infective endocarditis: impact of diabetes on mortality
title_full_unstemmed Surgical treatment on infective endocarditis: impact of diabetes on mortality
title_short Surgical treatment on infective endocarditis: impact of diabetes on mortality
title_sort surgical treatment on infective endocarditis: impact of diabetes on mortality
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248198/
https://www.ncbi.nlm.nih.gov/pubmed/35773698
http://dx.doi.org/10.1186/s12933-022-01557-x
work_keys_str_mv AT koganalexander surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT wiederfinesodanat surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT frogeljonathan surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT peledpotashnikyael surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT rameilon surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT raananiehud surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality
AT sternikleonid surgicaltreatmentoninfectiveendocarditisimpactofdiabetesonmortality